Isotechnika Inc.

Isotechnika Inc. Appoints International Pharmaceutical Business Leader to Board of Directors

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today the appointment of Patrice R.  Debregeas to its board of directors. As Chairman, CEO and President of  Ethypharm S.A, the leading drug delivery company in Europe, Mr. Debregeas  brings extensive international experience in the pharmaceutical sector. Under the supervision of Mr. Debregeas, Ethypharm has successfully launched 50 products in over 70 countries.

    Mr. Debregeas holds an MBA from Wharton Graduate School of Business at  the University of Pennsylvania and an M.S. in Pharmacy from the University  of Paris. "I am most excited to be joining the Board of Directors for  Isotechnika Inc., a Company that is developing a very strong pipeline of  therapeutic products and a new test for insulin resistance that could  change the diagnosis of diabetic patients worldwide," stated Mr. Debregeas.

    "It is both a pleasure and a privilege to welcome Patrice Debregeas to  our board of directors," stated Dr. Robert Foster, Isotechnika's Chairman  and CEO. "Mr. Debregeas' years of experience in the delivery of  pharmaceutical products will be a valuable asset as our lead drug candidate , ISA247 advances towards a Phase III psoriasis trial later this year."

    About Isotechnika Inc.

    ----------------------

    Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in  medicinal chemistry and immunology, the Company is focused on the discovery  and development of novel immunosuppressive therapeutics that are safer than  currently available treatments. Its entrepreneurial management and world- class team of scientists are building a pipeline of immunosuppressive drug  candidates for use in the prevention of organ rejection in transplantation  and in the treatment of autoimmune diseases. Isotechnika looks to become the leader in development of immunosuppressant therapies.

    Isotechnika's lead drug, ISA247, presently referred to as trans-ISA247,  is an immunosuppressant that has successfully completed a Phase II trial  for psoriasis and Phase IIa trial for kidney transplantation. Isotechnika  recently expanded its product pipeline by developing two additional novel  immunosuppressive compounds, TAFA93 and TKB662. TAFA93 is a novel small  molecule mTOR inhibitor, a class of drugs currently used in the prevention  of organ rejection in transplantation and as a coated stent therapy in the  treatment of coronary artery disease. Pre-clinical studies of TKB662 have  demonstrated inhibition of T cell and B cell activation and proliferation  through multiple mechanisms of action including the inhibition of  lymphocyte phosphorylation activity. As both TAFA93 and TKB662 have  distinct mechanisms of action from calcineurin inhibitors such as ISA247  they have the potential to be administered as complementary therapies in  both prevention of organ rejection and treatment of autoimmune diseases.

    In addition to the Company's drug pipeline, Isotechnika also has a diagnostic division, which includes the Helikit(TM) and Diatest(TM) breath  kits. The Helikit(TM), a (13)C breath test is used for the detection of H. pylori, a bacterium that infects a large portion of the population. The  Helikit(TM) is currently sold internationally. The Diatest(TM), a (13)C  glucose breath test is used for the detection of insulin resistance. The  Company expects to commence the necessary clinical trials in 2005 involving  the Diatest(TM) to obtain regulatory approval in the United States.

    Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.

    Forward-Looking Statements

    --------------------------

    This press release may contain forward-looking statements.
Forward-looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its  intellectual property, involve known and unknown risks and
uncertainties,  which could cause the Company's actual results to
differ materially from  those in the        forward-looking statements.
Such risks and uncertainties  include, among others, the availability
of funds and resources to pursue  research and development projects,
the ability to economically manufacture  its products, the potential
of its products, the success and timely  completion of clinical
studies and trials, the Company's ability to  successfully
commercialize its products, the ability of the Company to  defend its
patents from infringement by third parties, and the risk that  the
Company's patents may be subsequently shown to be invalid or infringe
the patents of others. Investors should consult the Company's
quarterly and  annual filings with the Canadian commissions for
additional information on  risks and uncertainties relating to the
forward-looking statements.  Investors are cautioned against placing
undue reliance on forward-looking statements.

    Archived images on this organization are available through CNW E-Pix at  http://www.newswire.ca. Images are free to members of The Canadian Press.  To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports@cnw.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.newsaktuell.ch

Contact:
For further information: Dr. Robert Foster, Chairman & CEO,
Isotechnika Inc., +1(780)-487-1600 ext. 246, +1(780)-484-4105 (fax),
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Manager,
Corporate Communications, Isotechnika Inc., +1(780)-487-1600 ext.
243, +1(780)-484-4105 (fax), sgillis-paulgaard@isotechnika.com



Weitere Meldungen: Isotechnika Inc.

Das könnte Sie auch interessieren: